MEDIA | The Pharma Letter
The Pharma Letter has published the news of Avecho’s ten-year development and licensing agreement with Sandoz (SWX: SDZ) for the commercial rights to its cannabidiol (CBD) capsule for insomnia in Australia.
Read the article.